S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ADCT ADC Therapeutics SA

1.51

0.00 (0.00%)

Pre Market

Last Updated: 07:03:19

Delayed by 15 minutes

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more ADC Therapeutics Charts.

ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more ADC Therapeutics Charts.

ADC Therapeutics SA News

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Monday 3 February 2025 (7 days ago) • Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Monday 3 February 2025 (7 days ago) • PR Newswire (US)

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Thursday 30 January 2025 (2 weeks ago) • PR Newswire (US)

Form 8-K - Current report
Monday 13 January 2025 (4 weeks ago) • Edgar (US Regulatory)

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Thursday 2 January 2025 (1 month ago) • PR Newswire (US)

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
Monday 30 December 2024 (1 month ago) • PR Newswire (US)

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Wednesday 11 December 2024 (2 months ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Monday 9 December 2024 (2 months ago) • Edgar (US Regulatory)

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
Monday 9 December 2024 (2 months ago) • PR Newswire (US)

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Friday 6 December 2024 (2 months ago) • PR Newswire (US)

More ADC Therapeutics SA News Articles

Kraig Biocraft Laborator... (QB)

RespireRx Pharmaceuticals (CE)

Intergrated Cannabis Sol... (PK)

North Bay Resources (PK)

NioCorp Developments

Rennova Health (CE)

Lightwave Logic

TheGlobe com (PK)

Bioelectronics (PK)

Elite Pharmaceuticals (QB)

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions